RedHill Biopharma Ltd. (RDHL) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.58

From 52W high−77.45%

Volume80563.00

Market cap$3.46M

P/E (TTM)—

P/S (TTM)12.1x

Div yield—

Key dataSep 18, 2026

Open

$0.58

From 52W high

−77.45%

Volume

80563.00

Market cap

$3.46M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

42.5

MomentumView details →

1D Return

−4.13%

YTD Return

−43.81%

SummaryUpdated Dec 1, 2025

RedHill Biopharma Ltd. (NASDAQ:RDHL) is a specialty biopharmaceutical company founded in 2009 and headquartered in Tel Aviv, Israel. The company went public in 2013 and focuses primarily on developing and commercializing treatments for gastrointestinal and infectious diseases. RedHill operates as a clinical-stage biopharmaceutical company with a portfolio of marketed products and an extensive pipeline of investigational drugs in various stages of development.

Ask drillr about RedHill Biopharma Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

2.8x

P/S (TTM)

12.1x

P/B (TTM)

−0.8x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−150.00%

EBITDA Margin

−2675.52%

ROE (TTM)

9.72%

ROA (TTM)

−2.33%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−83.34%

EPS CAGR 3Y

+100.00%

EBITDA YoY

—

MomentumView details →

1D Return

−4.13%

YTD Return

−43.81%

1Y Return

−65.75%

RSI (14)

42.5

vs 50D SMA

−11.98%

vs 200D SMA

−36.89%

Capital & dividendView details →

Debt/Equity

−0.05x

Current Ratio

0.56x

Quick Ratio

0.42x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.15

EPS Surprise

—

Beats (12Q)

2/12

Next Q EPS Est

−$352.86

Avg Surprise (4Q)

−140.63%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

9.55M

Net Income (TTM)

−9.31M

Op. CF (TTM)

−8.20M

Next earningsMar 18, 2027 →

Latest newsMore news →

RedHill acquired global commercialization rights to Ferring's Rebyota and Clenpiq.18d ago

RedHill Biopharma divested its 70% stake in Talicia to Apotex for an $18 million upfront cash payment plus up to $35 million in potential milestone payments.20d ago

Similar companies

Sunshine Biopharma, Inc.SBFM PRF Technologies Ltd.PRFX Shuttle Pharmaceuticals Holdings, Inc.SHPH China SXT Pharmaceuticals, Inc.SXTC IM Cannabis Corp.IMCC Procaps Group, S.A.PROCW Find similar companies →

Latest newsMore news →

RedHill acquired global commercialization rights to Ferring's Rebyota and Clenpiq.18d ago RedHill Biopharma divested its 70% stake in Talicia to Apotex for an $18 million upfront cash payment plus up to $35 million in potential milestone payments.20d ago